Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is ...

Q1 2025 Earnings Call Transcript April 29, 2025 Pfizer Inc. beats earnings expectations. Reported EPS is $0.92, expectations ...

CEOs have been grilled on tariffs and their impact on business and consumers' wallets in recent earnings calls and interviews ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Here's a list of the companies that have announced new U.S. investments since Trump took office: Merck on Tuesday said it is ...

David Denton; Executive Vice President, Chief Financial Officer; Pfizer Inc Aamir Malik; Executive Vice President, Chief US Commercial Officer; Pfizer Inc Alexandre De Germay; Executive Vice President ...

Entering trading on Monday, the S&P 500 has declined around 6% since the start of the year. Three stocks that are down over ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it can ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...